Ultragenyx Pharmaceutical (RARE) Other Non Operating Income (2013 - 2025)

Ultragenyx Pharmaceutical (RARE) has 13 years of Other Non Operating Income data on file, last reported at -$934000.0 in Q4 2025.

• Other Non Operating Income for Q4 2025 came in at -$934000.0, up 79.88% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.0 million (up 120.0% YoY), and the FY2025 annual result was $1.0 million, up 120.0% from the prior year.
• Other Non Operating Income improved to -$934000.0 in Q4 2025 per RARE's latest filing, from -$1.0 million in the prior quarter.
• Over five years, Other Non Operating Income peaked at $3.1 million in Q3 2024 and troughed at -$4.6 million in Q4 2024.
• A 5-year average of -$412650.0 and a median of -$557000.0 in 2021 frame the typical range for Other Non Operating Income.
• The sharpest annual moves came in 2022 and 2023: Other Non Operating Income plunged 1288.06% in 2022, then jumped 666.67% in 2023.
• A 5-year view of Other Non Operating Income shows it stood at -$410000.0 in 2021, then soared by 143.9% to $180000.0 in 2022, then jumped by 666.67% to $1.4 million in 2023, then plunged by 436.45% to -$4.6 million in 2024, then soared by 79.88% to -$934000.0 in 2025.
• Business Quant data shows RARE's Other Non Operating Income at -$934000.0 in Q4 2025, -$1.0 million in Q3 2025, and $2.1 million in Q2 2025.